There is a rising global prevalence of type 2 diabetes (T2D), which poses both health and economic burdens. Effective research on T2D and clinical interventions can decrease the impact of these burdens and fill knowledge gaps in their efficacy, safety, and long-term outcomes. This comprehensive literature-based review examines the role of the gut microbiome in T2D and treatments, such as metformin and scutellaria radix-coptidis rhizoma (SC) herb couple, for gut microbiome (GM) modulation and improvement in T2D. For the purposes of this thesis, the GM is defined as a healthy nondiabetic GM, whereas dysbiosis, a deviation from a healthy GM maybe associated with the pathogenesis of T2D in terms of glucose metabolism, insulin sensitivity and inflammatory pathways and dysbiosis has been observed in individuals with a diagnosis of T2D. Microbial metabolites, such as short chain fatty acids and bile acids, and inflammatory processes have been associated with diabetes-related outcomes. Metformin, a traditional first line antidiabetic agent, as well as the traditional Chinese medicine herb couple, SC, modulate the composition of the GM in alleviating T2D. Based on the current body of knowledge, we propose to further investigate the effect of metformin and SC on the GM in T2D alleviation and measure the composition of the GM before and after an interventional clinical trial period. Investigating the effects of these study drugs and their relation to the GM may provide new insights on the pathogenesis and management of T2D.
| Identifer | oai:union.ndltd.org:bu.edu/oai:open.bu.edu:2144/49499 |
| Date | 13 November 2024 |
| Creators | Tran, Kelley |
| Contributors | Weber, H. Christian, Weinstein, John R. |
| Source Sets | Boston University |
| Language | en_US |
| Detected Language | English |
| Type | Thesis/Dissertation |
| Rights | Attribution 4.0 International, http://creativecommons.org/licenses/by/4.0/ |
Page generated in 0.002 seconds